BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Juniper Biosciences LLC today announced the closing of an oversubscribed and upsized $40 million seed financing through its parent company, Juniper Radiopharma LLC, co-led by NovaCapital, several high-net-worth individuals, and members of the Club Degli Investitori. “We are thrilled to have the support of a diverse investor base who believe strongly in the promise that radiopharmaceuticals offer to the future of patient care.” said Alex Agnoletto, CEO. “O ...

Accessibility StatementSkip Navigation SOUTH SAN FRANCISCO, Calif. and SHANGHAI, Dec. 1, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial to evaluate IDE034, a potential first-in-class bispecific B7H3/PTK7 TOP1 antibody- ...

前一天摘要 – 2025年11月28日，星期五 美国主要指数 顶级股票搬运者 标普500指数：▲0.5355%，至6849.09美元 道琼斯：▲0.6100%，至47716.42美元 纳斯达克100指数：▲0.7844%，至25434.889美元 罗素2000年：▲0.5800%至2500.43美元 VIX：降-4.9971%，至16.35 美国十年期收益率： ▲0.4777%至4.0382% WTI原油：跌幅-0.1705%至58.55美元 黄金：▲0.3400%至4236.79美元 周五，美国股市收盘，连续第五天上涨，但这次反弹更像是一次试探性的"缓解反弹"，而非全面调整。 此次反弹得益于人们对美联储将在12月会议上降息的日益乐观，这一观点在近期经济数据和美联储鸽派 信号后愈发受到认可。不过，这次会议也并非没有紧张气氛。芝加哥商品交易所集团的技术故障导致当 天早些时候期货和股票合约交易冻结数小时，增加了不确定性并限制了缩短的假期交易时段的流动性。 与此同时，近期承受压力的主要科技和人工智能相关股票依然波动较大。这表明，虽然投资者欢迎短期 缓解，但许多人仍对高估值持谨慎态度，并密切关注宏观或政策变动的迹象。 ...

GUANGZHOU, China, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“AGM”) on December 23, 2025 at 10:30 a.m. (local time) at the Company’s Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai. The notice of ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 肝细胞癌 （HCC） 是 肝癌 的主要亚型，也是全球癌症相关死亡的主要原因之一，其发病率和死亡率一直 居高不下。 肿瘤相关巨噬细胞 （TAM） 在塑造 肝细胞癌 （HCC） 的免疫微环境中发挥着着关键作用， 影响肿瘤进展和免疫治疗反应。 N 7 -甲基鸟苷 （m 7 G） 是一 种常见的 RNA 表观遗传修饰， WDR4 是 m 7 G 甲基转 移酶复合物中的一 种 tRNA 结合辅助因子，但其独立功能仍知之甚少。 在这项最新研究中，研究团队发现， WDR4 在 肝细胞癌 （HCC） 相关的 肿瘤相关巨噬细胞 （TAM） 中 的表达显著上调，并与不良预后相关。 单核细胞来源的巨噬细胞中 WDR4 的缺失 （而不是驻留 Kupffer 细胞 中的 WDR4 缺失） ， 会将肿瘤相关巨噬细胞 （TAM） 编程为抗肿瘤表型，从而抑制肝细胞癌 （HCC） 的进展。 从机制上来说，细胞质中的 WDR4 通过直接与 eIF4E2 相互作用，独立于 m 7 G 修饰来增强 eIF4E 介导 的 ABCA1 的选择性翻译，从而促进膜胆固醇外流并维持促肿瘤极化。利用 CpG-siRNA ...

022-28451618 SAC NO：S1150511010016 cuijian@bhzq.com 崔健 渤海证券研究所晨会纪要（2025.12.01） 宏观及策略研究 联储降息仍存分歧，国内政策积极布局——宏观经济周报 固定收益研究 新征程，辨而明，变则通——信用债 2026 年投资策略 震荡中寻锚——利率债 2026 年投资策略展望 行业研究 晨会纪要（2025/12/01） 编辑人 国常会部署推进基本医保省级统筹——医药生物行业周报 证 券 研 究 报 告 晨 会 纪 要 请务必阅读正文之后的声明 渤海证券股份有限公司具备证券投资咨询业务资格 1 of 7 晨会纪要（2025/12/01） 宏观及策略研究 联储降息仍存分歧，国内政策积极布局——宏观经济周报 周 喜（证券分析师，SAC NO：S1150511010017） 宋亦威（证券分析师，SAC NO：S1150514080001） 严佩佩（证券分析师，SAC NO：S1150520110001） 靳沛芃（研究助理，SAC NO：S1150124030005） 1、就外围环境而言 美国方面，9 月零售销售虽维持正增，但表现不及预期，较前值明显放缓 ...

Core Viewpoint - Rosen Law Firm is encouraging investors of Telix Pharmaceuticals Ltd. to secure legal counsel before the January 9, 2026 deadline for a securities class action lawsuit related to the company's misleading statements during the class period from February 21, 2025, to August 28, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased Telix securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 9, 2026 [3][6]. - The lawsuit alleges that Telix made materially false and misleading statements regarding its prostate cancer therapeutic candidates and the quality of its supply chain, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in achieving significant settlements for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Skye Bioscience, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on January 16, 2026, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Skye securities between November 4, 2024, and October 3, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [2]. - The lawsuit alleges that Skye's defendants made materially false and misleading statements regarding the effectiveness and prospects of nimacimab, leading to investor damages when the truth was revealed [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in achieving significant settlements [3]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 in 2017 and consistently in the top 4 since 2013, recovering hundreds of millions for investors [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. due to allegations of misleading statements regarding the effectiveness of its drug nimacimab, which led to significant stock price declines following the release of disappointing clinical trial results [1][3][4]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Skye to contact them for discussing legal options, with a deadline of January 16, 2026, to seek the role of lead plaintiff in a federal securities class action [1][5]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [2]. Group 2: Allegations Against Skye - The complaint alleges that Skye and its executives violated federal securities laws by making false and misleading statements about nimacimab's effectiveness and overstating its clinical, regulatory, and commercial prospects [3]. - On October 6, 2025, Skye announced that its nimacimab did not achieve the primary endpoint of weight loss compared to placebo, resulting in a 60% drop in stock price, closing at $1.90 per share [4].

Last time I took a look at Atara Biotherapeutics ( ATRA ), I was intrigued and optimistic about their allogeneic (non-self) CAR T-cell therapy, in a novel indication for engineered cell therapies. But that has been quiteI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfa ...